GlassScriptPhysician profile
Chrystal Clamp
NPI 1265426050
$9,791.62
in general payments reported to CMS, 2019-2025
30 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $1,112 · 2021: $1,447 · 2022: $2,048 · 2023: $1,872 · 2024: $1,169 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,524.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,002.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,119.79 | 2019-2025 | |
| Abbvie INC. | $1,039.45 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Lilly USA, LLC | $981.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $797.35 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $789.99 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $361.07 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $325.49 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.87 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $290.30 | 2019-2023 | Xarelto, Spravato |
| Astellas Pharma US INC | $253.92 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $186.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $182.56 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $161.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.84 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $135.02 | 2019-2025 | Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $109.75 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.88 | 2019-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $82.26 | 2021 | |
| Abbott Laboratories | $78.85 | 2019-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $71.22 | 2023-2024 | Rexulti |
| Daiichi Sankyo INC. | $66.54 | 2019 | |
| Dynavax Technologies Corporation | $58.65 | 2023-2024 | Heplisav-B |
| Eisai INC. | $45.09 | 2020-2021 | |
| Gilead Sciences, INC. | $42.30 | 2020-2025 | |
| Si-Bone, INC. | $20.28 | 2025 | |
| Neuronetics, INC. | $18.30 | 2019 | |
| Shield Therapeutics INC | $14.94 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.38 | 2023 | Quviviq |
| Mannkind Corporation | $13.17 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrystal Clamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.